Enhancement of kinase selectivity in a potent class of arylamide FMS inhibitors
Abstract Structure–activity relationship (SAR) studies on a highly potent series of arylamide FMS inhibitors were carried out with the aim of improving FMS kinase selectivity, particularly over KIT. Potent compound 17r (FMS IC50 0.7nM, FMS cell IC50 6.1nM) was discovered that had good PK properties...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Illig, Carl R. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2013transfer abstract |
|---|
| Schlagwörter: |
Colony-stimulating factor-1 receptor |
|---|
| Umfang: |
7 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Feeding European sea bass ( - Torrecillas, S. ELSEVIER, 2018, a Tetrahedron publication for rapid dissemination of preliminary communications on all aspects of bioorganic chemistry, medicinal chemistry, bioinorganic chemistry and related disciplines, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:23 ; year:2013 ; number:23 ; day:1 ; month:12 ; pages:6363-6369 ; extent:7 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.bmcl.2013.09.061 |
|---|
| Katalog-ID: |
ELV011755504 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV011755504 | ||
| 003 | DE-627 | ||
| 005 | 20230625110201.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180602s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.bmcl.2013.09.061 |2 doi | |
| 028 | 5 | 2 | |a GBVA2013016000014.pica |
| 035 | |a (DE-627)ELV011755504 | ||
| 035 | |a (ELSEVIER)S0960-894X(13)01135-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 540 |a 610 | |
| 082 | 0 | 4 | |a 540 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 630 |q VZ |
| 084 | |a 22 |2 ssgn | ||
| 084 | |a 46.00 |2 bkl | ||
| 100 | 1 | |a Illig, Carl R. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Enhancement of kinase selectivity in a potent class of arylamide FMS inhibitors |
| 264 | 1 | |c 2013transfer abstract | |
| 300 | |a 7 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Abstract Structure–activity relationship (SAR) studies on a highly potent series of arylamide FMS inhibitors were carried out with the aim of improving FMS kinase selectivity, particularly over KIT. Potent compound 17r (FMS IC50 0.7nM, FMS cell IC50 6.1nM) was discovered that had good PK properties and a greater than fivefold improvement in selectivity for FMS over KIT kinase in a cellular assay relative to the previously reported clinical candidate 4. This improved selectivity was manifested in vivo by no observed decrease in circulating reticulocytes, a measure of bone safety, at the highest studied dose. Compound 17r was highly active in a mouse pharmacodynamic model and demonstrated disease-modifying effects in a dose-dependent manner in a strep cell wall-induced arthritis model of rheumatoid arthritis in rats. | ||
| 520 | |a Abstract Structure–activity relationship (SAR) studies on a highly potent series of arylamide FMS inhibitors were carried out with the aim of improving FMS kinase selectivity, particularly over KIT. Potent compound 17r (FMS IC50 0.7nM, FMS cell IC50 6.1nM) was discovered that had good PK properties and a greater than fivefold improvement in selectivity for FMS over KIT kinase in a cellular assay relative to the previously reported clinical candidate 4. This improved selectivity was manifested in vivo by no observed decrease in circulating reticulocytes, a measure of bone safety, at the highest studied dose. Compound 17r was highly active in a mouse pharmacodynamic model and demonstrated disease-modifying effects in a dose-dependent manner in a strep cell wall-induced arthritis model of rheumatoid arthritis in rats. | ||
| 650 | 7 | |a Rheumatoid arthritis |2 Elsevier | |
| 650 | 7 | |a Colony-stimulating factor-1 receptor |2 Elsevier | |
| 650 | 7 | |a Macrophage colony-stimulating factor |2 Elsevier | |
| 650 | 7 | |a KIT |2 Elsevier | |
| 650 | 7 | |a Hypocellularity |2 Elsevier | |
| 650 | 7 | |a FMS |2 Elsevier | |
| 650 | 7 | |a Anti-inflammatory |2 Elsevier | |
| 700 | 1 | |a Manthey, Carl L. |4 oth | |
| 700 | 1 | |a Meegalla, Sanath K. |4 oth | |
| 700 | 1 | |a Wall, Mark J. |4 oth | |
| 700 | 1 | |a Chen, Jinsheng |4 oth | |
| 700 | 1 | |a Wilson, Kenneth J. |4 oth | |
| 700 | 1 | |a DesJarlais, Renee L. |4 oth | |
| 700 | 1 | |a Ballentine, Shelley K. |4 oth | |
| 700 | 1 | |a Schubert, Carsten |4 oth | |
| 700 | 1 | |a Crysler, Carl S. |4 oth | |
| 700 | 1 | |a Chen, Yanmin |4 oth | |
| 700 | 1 | |a Molloy, Christopher J. |4 oth | |
| 700 | 1 | |a Chaikin, Margery A. |4 oth | |
| 700 | 1 | |a Donatelli, Robert R. |4 oth | |
| 700 | 1 | |a Yurkow, Edward |4 oth | |
| 700 | 1 | |a Zhou, Zhao |4 oth | |
| 700 | 1 | |a Player, Mark R. |4 oth | |
| 700 | 1 | |a Tomczuk, Bruce E. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Torrecillas, S. ELSEVIER |t Feeding European sea bass ( |d 2018 |d a Tetrahedron publication for rapid dissemination of preliminary communications on all aspects of bioorganic chemistry, medicinal chemistry, bioinorganic chemistry and related disciplines |g Amsterdam [u.a.] |w (DE-627)ELV000272361 |
| 773 | 1 | 8 | |g volume:23 |g year:2013 |g number:23 |g day:1 |g month:12 |g pages:6363-6369 |g extent:7 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.bmcl.2013.09.061 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 936 | b | k | |a 46.00 |j Tiermedizin: Allgemeines |q VZ |
| 951 | |a AR | ||
| 952 | |d 23 |j 2013 |e 23 |b 1 |c 1201 |h 6363-6369 |g 7 | ||
| 953 | |2 045F |a 540 | ||
| author_variant |
c r i cr cri |
|---|---|
| matchkey_str |
illigcarlrmantheycarllmeegallasanathkwal:2013----:nacmnoknsslciiynptncasfrl |
| hierarchy_sort_str |
2013transfer abstract |
| bklnumber |
46.00 |
| publishDate |
2013 |
| allfields |
10.1016/j.bmcl.2013.09.061 doi GBVA2013016000014.pica (DE-627)ELV011755504 (ELSEVIER)S0960-894X(13)01135-9 DE-627 ger DE-627 rakwb eng 540 610 540 DE-600 610 DE-600 630 VZ 22 ssgn 46.00 bkl Illig, Carl R. verfasserin aut Enhancement of kinase selectivity in a potent class of arylamide FMS inhibitors 2013transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract Structure–activity relationship (SAR) studies on a highly potent series of arylamide FMS inhibitors were carried out with the aim of improving FMS kinase selectivity, particularly over KIT. Potent compound 17r (FMS IC50 0.7nM, FMS cell IC50 6.1nM) was discovered that had good PK properties and a greater than fivefold improvement in selectivity for FMS over KIT kinase in a cellular assay relative to the previously reported clinical candidate 4. This improved selectivity was manifested in vivo by no observed decrease in circulating reticulocytes, a measure of bone safety, at the highest studied dose. Compound 17r was highly active in a mouse pharmacodynamic model and demonstrated disease-modifying effects in a dose-dependent manner in a strep cell wall-induced arthritis model of rheumatoid arthritis in rats. Abstract Structure–activity relationship (SAR) studies on a highly potent series of arylamide FMS inhibitors were carried out with the aim of improving FMS kinase selectivity, particularly over KIT. Potent compound 17r (FMS IC50 0.7nM, FMS cell IC50 6.1nM) was discovered that had good PK properties and a greater than fivefold improvement in selectivity for FMS over KIT kinase in a cellular assay relative to the previously reported clinical candidate 4. This improved selectivity was manifested in vivo by no observed decrease in circulating reticulocytes, a measure of bone safety, at the highest studied dose. Compound 17r was highly active in a mouse pharmacodynamic model and demonstrated disease-modifying effects in a dose-dependent manner in a strep cell wall-induced arthritis model of rheumatoid arthritis in rats. Rheumatoid arthritis Elsevier Colony-stimulating factor-1 receptor Elsevier Macrophage colony-stimulating factor Elsevier KIT Elsevier Hypocellularity Elsevier FMS Elsevier Anti-inflammatory Elsevier Manthey, Carl L. oth Meegalla, Sanath K. oth Wall, Mark J. oth Chen, Jinsheng oth Wilson, Kenneth J. oth DesJarlais, Renee L. oth Ballentine, Shelley K. oth Schubert, Carsten oth Crysler, Carl S. oth Chen, Yanmin oth Molloy, Christopher J. oth Chaikin, Margery A. oth Donatelli, Robert R. oth Yurkow, Edward oth Zhou, Zhao oth Player, Mark R. oth Tomczuk, Bruce E. oth Enthalten in Elsevier Science Torrecillas, S. ELSEVIER Feeding European sea bass ( 2018 a Tetrahedron publication for rapid dissemination of preliminary communications on all aspects of bioorganic chemistry, medicinal chemistry, bioinorganic chemistry and related disciplines Amsterdam [u.a.] (DE-627)ELV000272361 volume:23 year:2013 number:23 day:1 month:12 pages:6363-6369 extent:7 https://doi.org/10.1016/j.bmcl.2013.09.061 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 46.00 Tiermedizin: Allgemeines VZ AR 23 2013 23 1 1201 6363-6369 7 045F 540 |
| spelling |
10.1016/j.bmcl.2013.09.061 doi GBVA2013016000014.pica (DE-627)ELV011755504 (ELSEVIER)S0960-894X(13)01135-9 DE-627 ger DE-627 rakwb eng 540 610 540 DE-600 610 DE-600 630 VZ 22 ssgn 46.00 bkl Illig, Carl R. verfasserin aut Enhancement of kinase selectivity in a potent class of arylamide FMS inhibitors 2013transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract Structure–activity relationship (SAR) studies on a highly potent series of arylamide FMS inhibitors were carried out with the aim of improving FMS kinase selectivity, particularly over KIT. Potent compound 17r (FMS IC50 0.7nM, FMS cell IC50 6.1nM) was discovered that had good PK properties and a greater than fivefold improvement in selectivity for FMS over KIT kinase in a cellular assay relative to the previously reported clinical candidate 4. This improved selectivity was manifested in vivo by no observed decrease in circulating reticulocytes, a measure of bone safety, at the highest studied dose. Compound 17r was highly active in a mouse pharmacodynamic model and demonstrated disease-modifying effects in a dose-dependent manner in a strep cell wall-induced arthritis model of rheumatoid arthritis in rats. Abstract Structure–activity relationship (SAR) studies on a highly potent series of arylamide FMS inhibitors were carried out with the aim of improving FMS kinase selectivity, particularly over KIT. Potent compound 17r (FMS IC50 0.7nM, FMS cell IC50 6.1nM) was discovered that had good PK properties and a greater than fivefold improvement in selectivity for FMS over KIT kinase in a cellular assay relative to the previously reported clinical candidate 4. This improved selectivity was manifested in vivo by no observed decrease in circulating reticulocytes, a measure of bone safety, at the highest studied dose. Compound 17r was highly active in a mouse pharmacodynamic model and demonstrated disease-modifying effects in a dose-dependent manner in a strep cell wall-induced arthritis model of rheumatoid arthritis in rats. Rheumatoid arthritis Elsevier Colony-stimulating factor-1 receptor Elsevier Macrophage colony-stimulating factor Elsevier KIT Elsevier Hypocellularity Elsevier FMS Elsevier Anti-inflammatory Elsevier Manthey, Carl L. oth Meegalla, Sanath K. oth Wall, Mark J. oth Chen, Jinsheng oth Wilson, Kenneth J. oth DesJarlais, Renee L. oth Ballentine, Shelley K. oth Schubert, Carsten oth Crysler, Carl S. oth Chen, Yanmin oth Molloy, Christopher J. oth Chaikin, Margery A. oth Donatelli, Robert R. oth Yurkow, Edward oth Zhou, Zhao oth Player, Mark R. oth Tomczuk, Bruce E. oth Enthalten in Elsevier Science Torrecillas, S. ELSEVIER Feeding European sea bass ( 2018 a Tetrahedron publication for rapid dissemination of preliminary communications on all aspects of bioorganic chemistry, medicinal chemistry, bioinorganic chemistry and related disciplines Amsterdam [u.a.] (DE-627)ELV000272361 volume:23 year:2013 number:23 day:1 month:12 pages:6363-6369 extent:7 https://doi.org/10.1016/j.bmcl.2013.09.061 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 46.00 Tiermedizin: Allgemeines VZ AR 23 2013 23 1 1201 6363-6369 7 045F 540 |
| allfields_unstemmed |
10.1016/j.bmcl.2013.09.061 doi GBVA2013016000014.pica (DE-627)ELV011755504 (ELSEVIER)S0960-894X(13)01135-9 DE-627 ger DE-627 rakwb eng 540 610 540 DE-600 610 DE-600 630 VZ 22 ssgn 46.00 bkl Illig, Carl R. verfasserin aut Enhancement of kinase selectivity in a potent class of arylamide FMS inhibitors 2013transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract Structure–activity relationship (SAR) studies on a highly potent series of arylamide FMS inhibitors were carried out with the aim of improving FMS kinase selectivity, particularly over KIT. Potent compound 17r (FMS IC50 0.7nM, FMS cell IC50 6.1nM) was discovered that had good PK properties and a greater than fivefold improvement in selectivity for FMS over KIT kinase in a cellular assay relative to the previously reported clinical candidate 4. This improved selectivity was manifested in vivo by no observed decrease in circulating reticulocytes, a measure of bone safety, at the highest studied dose. Compound 17r was highly active in a mouse pharmacodynamic model and demonstrated disease-modifying effects in a dose-dependent manner in a strep cell wall-induced arthritis model of rheumatoid arthritis in rats. Abstract Structure–activity relationship (SAR) studies on a highly potent series of arylamide FMS inhibitors were carried out with the aim of improving FMS kinase selectivity, particularly over KIT. Potent compound 17r (FMS IC50 0.7nM, FMS cell IC50 6.1nM) was discovered that had good PK properties and a greater than fivefold improvement in selectivity for FMS over KIT kinase in a cellular assay relative to the previously reported clinical candidate 4. This improved selectivity was manifested in vivo by no observed decrease in circulating reticulocytes, a measure of bone safety, at the highest studied dose. Compound 17r was highly active in a mouse pharmacodynamic model and demonstrated disease-modifying effects in a dose-dependent manner in a strep cell wall-induced arthritis model of rheumatoid arthritis in rats. Rheumatoid arthritis Elsevier Colony-stimulating factor-1 receptor Elsevier Macrophage colony-stimulating factor Elsevier KIT Elsevier Hypocellularity Elsevier FMS Elsevier Anti-inflammatory Elsevier Manthey, Carl L. oth Meegalla, Sanath K. oth Wall, Mark J. oth Chen, Jinsheng oth Wilson, Kenneth J. oth DesJarlais, Renee L. oth Ballentine, Shelley K. oth Schubert, Carsten oth Crysler, Carl S. oth Chen, Yanmin oth Molloy, Christopher J. oth Chaikin, Margery A. oth Donatelli, Robert R. oth Yurkow, Edward oth Zhou, Zhao oth Player, Mark R. oth Tomczuk, Bruce E. oth Enthalten in Elsevier Science Torrecillas, S. ELSEVIER Feeding European sea bass ( 2018 a Tetrahedron publication for rapid dissemination of preliminary communications on all aspects of bioorganic chemistry, medicinal chemistry, bioinorganic chemistry and related disciplines Amsterdam [u.a.] (DE-627)ELV000272361 volume:23 year:2013 number:23 day:1 month:12 pages:6363-6369 extent:7 https://doi.org/10.1016/j.bmcl.2013.09.061 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 46.00 Tiermedizin: Allgemeines VZ AR 23 2013 23 1 1201 6363-6369 7 045F 540 |
| allfieldsGer |
10.1016/j.bmcl.2013.09.061 doi GBVA2013016000014.pica (DE-627)ELV011755504 (ELSEVIER)S0960-894X(13)01135-9 DE-627 ger DE-627 rakwb eng 540 610 540 DE-600 610 DE-600 630 VZ 22 ssgn 46.00 bkl Illig, Carl R. verfasserin aut Enhancement of kinase selectivity in a potent class of arylamide FMS inhibitors 2013transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract Structure–activity relationship (SAR) studies on a highly potent series of arylamide FMS inhibitors were carried out with the aim of improving FMS kinase selectivity, particularly over KIT. Potent compound 17r (FMS IC50 0.7nM, FMS cell IC50 6.1nM) was discovered that had good PK properties and a greater than fivefold improvement in selectivity for FMS over KIT kinase in a cellular assay relative to the previously reported clinical candidate 4. This improved selectivity was manifested in vivo by no observed decrease in circulating reticulocytes, a measure of bone safety, at the highest studied dose. Compound 17r was highly active in a mouse pharmacodynamic model and demonstrated disease-modifying effects in a dose-dependent manner in a strep cell wall-induced arthritis model of rheumatoid arthritis in rats. Abstract Structure–activity relationship (SAR) studies on a highly potent series of arylamide FMS inhibitors were carried out with the aim of improving FMS kinase selectivity, particularly over KIT. Potent compound 17r (FMS IC50 0.7nM, FMS cell IC50 6.1nM) was discovered that had good PK properties and a greater than fivefold improvement in selectivity for FMS over KIT kinase in a cellular assay relative to the previously reported clinical candidate 4. This improved selectivity was manifested in vivo by no observed decrease in circulating reticulocytes, a measure of bone safety, at the highest studied dose. Compound 17r was highly active in a mouse pharmacodynamic model and demonstrated disease-modifying effects in a dose-dependent manner in a strep cell wall-induced arthritis model of rheumatoid arthritis in rats. Rheumatoid arthritis Elsevier Colony-stimulating factor-1 receptor Elsevier Macrophage colony-stimulating factor Elsevier KIT Elsevier Hypocellularity Elsevier FMS Elsevier Anti-inflammatory Elsevier Manthey, Carl L. oth Meegalla, Sanath K. oth Wall, Mark J. oth Chen, Jinsheng oth Wilson, Kenneth J. oth DesJarlais, Renee L. oth Ballentine, Shelley K. oth Schubert, Carsten oth Crysler, Carl S. oth Chen, Yanmin oth Molloy, Christopher J. oth Chaikin, Margery A. oth Donatelli, Robert R. oth Yurkow, Edward oth Zhou, Zhao oth Player, Mark R. oth Tomczuk, Bruce E. oth Enthalten in Elsevier Science Torrecillas, S. ELSEVIER Feeding European sea bass ( 2018 a Tetrahedron publication for rapid dissemination of preliminary communications on all aspects of bioorganic chemistry, medicinal chemistry, bioinorganic chemistry and related disciplines Amsterdam [u.a.] (DE-627)ELV000272361 volume:23 year:2013 number:23 day:1 month:12 pages:6363-6369 extent:7 https://doi.org/10.1016/j.bmcl.2013.09.061 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 46.00 Tiermedizin: Allgemeines VZ AR 23 2013 23 1 1201 6363-6369 7 045F 540 |
| allfieldsSound |
10.1016/j.bmcl.2013.09.061 doi GBVA2013016000014.pica (DE-627)ELV011755504 (ELSEVIER)S0960-894X(13)01135-9 DE-627 ger DE-627 rakwb eng 540 610 540 DE-600 610 DE-600 630 VZ 22 ssgn 46.00 bkl Illig, Carl R. verfasserin aut Enhancement of kinase selectivity in a potent class of arylamide FMS inhibitors 2013transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract Structure–activity relationship (SAR) studies on a highly potent series of arylamide FMS inhibitors were carried out with the aim of improving FMS kinase selectivity, particularly over KIT. Potent compound 17r (FMS IC50 0.7nM, FMS cell IC50 6.1nM) was discovered that had good PK properties and a greater than fivefold improvement in selectivity for FMS over KIT kinase in a cellular assay relative to the previously reported clinical candidate 4. This improved selectivity was manifested in vivo by no observed decrease in circulating reticulocytes, a measure of bone safety, at the highest studied dose. Compound 17r was highly active in a mouse pharmacodynamic model and demonstrated disease-modifying effects in a dose-dependent manner in a strep cell wall-induced arthritis model of rheumatoid arthritis in rats. Abstract Structure–activity relationship (SAR) studies on a highly potent series of arylamide FMS inhibitors were carried out with the aim of improving FMS kinase selectivity, particularly over KIT. Potent compound 17r (FMS IC50 0.7nM, FMS cell IC50 6.1nM) was discovered that had good PK properties and a greater than fivefold improvement in selectivity for FMS over KIT kinase in a cellular assay relative to the previously reported clinical candidate 4. This improved selectivity was manifested in vivo by no observed decrease in circulating reticulocytes, a measure of bone safety, at the highest studied dose. Compound 17r was highly active in a mouse pharmacodynamic model and demonstrated disease-modifying effects in a dose-dependent manner in a strep cell wall-induced arthritis model of rheumatoid arthritis in rats. Rheumatoid arthritis Elsevier Colony-stimulating factor-1 receptor Elsevier Macrophage colony-stimulating factor Elsevier KIT Elsevier Hypocellularity Elsevier FMS Elsevier Anti-inflammatory Elsevier Manthey, Carl L. oth Meegalla, Sanath K. oth Wall, Mark J. oth Chen, Jinsheng oth Wilson, Kenneth J. oth DesJarlais, Renee L. oth Ballentine, Shelley K. oth Schubert, Carsten oth Crysler, Carl S. oth Chen, Yanmin oth Molloy, Christopher J. oth Chaikin, Margery A. oth Donatelli, Robert R. oth Yurkow, Edward oth Zhou, Zhao oth Player, Mark R. oth Tomczuk, Bruce E. oth Enthalten in Elsevier Science Torrecillas, S. ELSEVIER Feeding European sea bass ( 2018 a Tetrahedron publication for rapid dissemination of preliminary communications on all aspects of bioorganic chemistry, medicinal chemistry, bioinorganic chemistry and related disciplines Amsterdam [u.a.] (DE-627)ELV000272361 volume:23 year:2013 number:23 day:1 month:12 pages:6363-6369 extent:7 https://doi.org/10.1016/j.bmcl.2013.09.061 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 46.00 Tiermedizin: Allgemeines VZ AR 23 2013 23 1 1201 6363-6369 7 045F 540 |
| language |
English |
| source |
Enthalten in Feeding European sea bass ( Amsterdam [u.a.] volume:23 year:2013 number:23 day:1 month:12 pages:6363-6369 extent:7 |
| sourceStr |
Enthalten in Feeding European sea bass ( Amsterdam [u.a.] volume:23 year:2013 number:23 day:1 month:12 pages:6363-6369 extent:7 |
| format_phy_str_mv |
Article |
| bklname |
Tiermedizin: Allgemeines |
| institution |
findex.gbv.de |
| topic_facet |
Rheumatoid arthritis Colony-stimulating factor-1 receptor Macrophage colony-stimulating factor KIT Hypocellularity FMS Anti-inflammatory |
| dewey-raw |
540 |
| isfreeaccess_bool |
false |
| container_title |
Feeding European sea bass ( |
| authorswithroles_txt_mv |
Illig, Carl R. @@aut@@ Manthey, Carl L. @@oth@@ Meegalla, Sanath K. @@oth@@ Wall, Mark J. @@oth@@ Chen, Jinsheng @@oth@@ Wilson, Kenneth J. @@oth@@ DesJarlais, Renee L. @@oth@@ Ballentine, Shelley K. @@oth@@ Schubert, Carsten @@oth@@ Crysler, Carl S. @@oth@@ Chen, Yanmin @@oth@@ Molloy, Christopher J. @@oth@@ Chaikin, Margery A. @@oth@@ Donatelli, Robert R. @@oth@@ Yurkow, Edward @@oth@@ Zhou, Zhao @@oth@@ Player, Mark R. @@oth@@ Tomczuk, Bruce E. @@oth@@ |
| publishDateDaySort_date |
2013-01-01T00:00:00Z |
| hierarchy_top_id |
ELV000272361 |
| dewey-sort |
3540 |
| id |
ELV011755504 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV011755504</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625110201.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2013 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.bmcl.2013.09.061</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2013016000014.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV011755504</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0960-894X(13)01135-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">540</subfield><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">630</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">22</subfield><subfield code="2">ssgn</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">46.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Illig, Carl R.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Enhancement of kinase selectivity in a potent class of arylamide FMS inhibitors</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Structure–activity relationship (SAR) studies on a highly potent series of arylamide FMS inhibitors were carried out with the aim of improving FMS kinase selectivity, particularly over KIT. Potent compound 17r (FMS IC50 0.7nM, FMS cell IC50 6.1nM) was discovered that had good PK properties and a greater than fivefold improvement in selectivity for FMS over KIT kinase in a cellular assay relative to the previously reported clinical candidate 4. This improved selectivity was manifested in vivo by no observed decrease in circulating reticulocytes, a measure of bone safety, at the highest studied dose. Compound 17r was highly active in a mouse pharmacodynamic model and demonstrated disease-modifying effects in a dose-dependent manner in a strep cell wall-induced arthritis model of rheumatoid arthritis in rats.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Structure–activity relationship (SAR) studies on a highly potent series of arylamide FMS inhibitors were carried out with the aim of improving FMS kinase selectivity, particularly over KIT. Potent compound 17r (FMS IC50 0.7nM, FMS cell IC50 6.1nM) was discovered that had good PK properties and a greater than fivefold improvement in selectivity for FMS over KIT kinase in a cellular assay relative to the previously reported clinical candidate 4. This improved selectivity was manifested in vivo by no observed decrease in circulating reticulocytes, a measure of bone safety, at the highest studied dose. Compound 17r was highly active in a mouse pharmacodynamic model and demonstrated disease-modifying effects in a dose-dependent manner in a strep cell wall-induced arthritis model of rheumatoid arthritis in rats.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Rheumatoid arthritis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Colony-stimulating factor-1 receptor</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Macrophage colony-stimulating factor</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">KIT</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Hypocellularity</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">FMS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Anti-inflammatory</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Manthey, Carl L.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Meegalla, Sanath K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wall, Mark J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chen, Jinsheng</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wilson, Kenneth J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">DesJarlais, Renee L.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ballentine, Shelley K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schubert, Carsten</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Crysler, Carl S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chen, Yanmin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Molloy, Christopher J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chaikin, Margery A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Donatelli, Robert R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yurkow, Edward</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhou, Zhao</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Player, Mark R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tomczuk, Bruce E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Torrecillas, S. ELSEVIER</subfield><subfield code="t">Feeding European sea bass (</subfield><subfield code="d">2018</subfield><subfield code="d">a Tetrahedron publication for rapid dissemination of preliminary communications on all aspects of bioorganic chemistry, medicinal chemistry, bioinorganic chemistry and related disciplines</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000272361</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:23</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:23</subfield><subfield code="g">day:1</subfield><subfield code="g">month:12</subfield><subfield code="g">pages:6363-6369</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.bmcl.2013.09.061</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">46.00</subfield><subfield code="j">Tiermedizin: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">23</subfield><subfield code="j">2013</subfield><subfield code="e">23</subfield><subfield code="b">1</subfield><subfield code="c">1201</subfield><subfield code="h">6363-6369</subfield><subfield code="g">7</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">540</subfield></datafield></record></collection>
|
| author |
Illig, Carl R. |
| spellingShingle |
Illig, Carl R. ddc 540 ddc 610 ddc 630 ssgn 22 bkl 46.00 Elsevier Rheumatoid arthritis Elsevier Colony-stimulating factor-1 receptor Elsevier Macrophage colony-stimulating factor Elsevier KIT Elsevier Hypocellularity Elsevier FMS Elsevier Anti-inflammatory Enhancement of kinase selectivity in a potent class of arylamide FMS inhibitors |
| authorStr |
Illig, Carl R. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV000272361 |
| format |
electronic Article |
| dewey-ones |
540 - Chemistry & allied sciences 610 - Medicine & health 630 - Agriculture & related technologies |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
540 610 540 DE-600 610 DE-600 630 VZ 22 ssgn 46.00 bkl Enhancement of kinase selectivity in a potent class of arylamide FMS inhibitors Rheumatoid arthritis Elsevier Colony-stimulating factor-1 receptor Elsevier Macrophage colony-stimulating factor Elsevier KIT Elsevier Hypocellularity Elsevier FMS Elsevier Anti-inflammatory Elsevier |
| topic |
ddc 540 ddc 610 ddc 630 ssgn 22 bkl 46.00 Elsevier Rheumatoid arthritis Elsevier Colony-stimulating factor-1 receptor Elsevier Macrophage colony-stimulating factor Elsevier KIT Elsevier Hypocellularity Elsevier FMS Elsevier Anti-inflammatory |
| topic_unstemmed |
ddc 540 ddc 610 ddc 630 ssgn 22 bkl 46.00 Elsevier Rheumatoid arthritis Elsevier Colony-stimulating factor-1 receptor Elsevier Macrophage colony-stimulating factor Elsevier KIT Elsevier Hypocellularity Elsevier FMS Elsevier Anti-inflammatory |
| topic_browse |
ddc 540 ddc 610 ddc 630 ssgn 22 bkl 46.00 Elsevier Rheumatoid arthritis Elsevier Colony-stimulating factor-1 receptor Elsevier Macrophage colony-stimulating factor Elsevier KIT Elsevier Hypocellularity Elsevier FMS Elsevier Anti-inflammatory |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
c l m cl clm s k m sk skm m j w mj mjw j c jc k j w kj kjw r l d rl rld s k b sk skb c s cs c s c cs csc y c yc c j m cj cjm m a c ma mac r r d rr rrd e y ey z z zz m r p mr mrp b e t be bet |
| hierarchy_parent_title |
Feeding European sea bass ( |
| hierarchy_parent_id |
ELV000272361 |
| dewey-tens |
540 - Chemistry 610 - Medicine & health 630 - Agriculture |
| hierarchy_top_title |
Feeding European sea bass ( |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV000272361 |
| title |
Enhancement of kinase selectivity in a potent class of arylamide FMS inhibitors |
| ctrlnum |
(DE-627)ELV011755504 (ELSEVIER)S0960-894X(13)01135-9 |
| title_full |
Enhancement of kinase selectivity in a potent class of arylamide FMS inhibitors |
| author_sort |
Illig, Carl R. |
| journal |
Feeding European sea bass ( |
| journalStr |
Feeding European sea bass ( |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
500 - Science 600 - Technology |
| recordtype |
marc |
| publishDateSort |
2013 |
| contenttype_str_mv |
zzz |
| container_start_page |
6363 |
| author_browse |
Illig, Carl R. |
| container_volume |
23 |
| physical |
7 |
| class |
540 610 540 DE-600 610 DE-600 630 VZ 22 ssgn 46.00 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Illig, Carl R. |
| doi_str_mv |
10.1016/j.bmcl.2013.09.061 |
| dewey-full |
540 610 630 |
| title_sort |
enhancement of kinase selectivity in a potent class of arylamide fms inhibitors |
| title_auth |
Enhancement of kinase selectivity in a potent class of arylamide FMS inhibitors |
| abstract |
Abstract Structure–activity relationship (SAR) studies on a highly potent series of arylamide FMS inhibitors were carried out with the aim of improving FMS kinase selectivity, particularly over KIT. Potent compound 17r (FMS IC50 0.7nM, FMS cell IC50 6.1nM) was discovered that had good PK properties and a greater than fivefold improvement in selectivity for FMS over KIT kinase in a cellular assay relative to the previously reported clinical candidate 4. This improved selectivity was manifested in vivo by no observed decrease in circulating reticulocytes, a measure of bone safety, at the highest studied dose. Compound 17r was highly active in a mouse pharmacodynamic model and demonstrated disease-modifying effects in a dose-dependent manner in a strep cell wall-induced arthritis model of rheumatoid arthritis in rats. |
| abstractGer |
Abstract Structure–activity relationship (SAR) studies on a highly potent series of arylamide FMS inhibitors were carried out with the aim of improving FMS kinase selectivity, particularly over KIT. Potent compound 17r (FMS IC50 0.7nM, FMS cell IC50 6.1nM) was discovered that had good PK properties and a greater than fivefold improvement in selectivity for FMS over KIT kinase in a cellular assay relative to the previously reported clinical candidate 4. This improved selectivity was manifested in vivo by no observed decrease in circulating reticulocytes, a measure of bone safety, at the highest studied dose. Compound 17r was highly active in a mouse pharmacodynamic model and demonstrated disease-modifying effects in a dose-dependent manner in a strep cell wall-induced arthritis model of rheumatoid arthritis in rats. |
| abstract_unstemmed |
Abstract Structure–activity relationship (SAR) studies on a highly potent series of arylamide FMS inhibitors were carried out with the aim of improving FMS kinase selectivity, particularly over KIT. Potent compound 17r (FMS IC50 0.7nM, FMS cell IC50 6.1nM) was discovered that had good PK properties and a greater than fivefold improvement in selectivity for FMS over KIT kinase in a cellular assay relative to the previously reported clinical candidate 4. This improved selectivity was manifested in vivo by no observed decrease in circulating reticulocytes, a measure of bone safety, at the highest studied dose. Compound 17r was highly active in a mouse pharmacodynamic model and demonstrated disease-modifying effects in a dose-dependent manner in a strep cell wall-induced arthritis model of rheumatoid arthritis in rats. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| container_issue |
23 |
| title_short |
Enhancement of kinase selectivity in a potent class of arylamide FMS inhibitors |
| url |
https://doi.org/10.1016/j.bmcl.2013.09.061 |
| remote_bool |
true |
| author2 |
Manthey, Carl L. Meegalla, Sanath K. Wall, Mark J. Chen, Jinsheng Wilson, Kenneth J. DesJarlais, Renee L. Ballentine, Shelley K. Schubert, Carsten Crysler, Carl S. Chen, Yanmin Molloy, Christopher J. Chaikin, Margery A. Donatelli, Robert R. Yurkow, Edward Zhou, Zhao Player, Mark R. Tomczuk, Bruce E. |
| author2Str |
Manthey, Carl L. Meegalla, Sanath K. Wall, Mark J. Chen, Jinsheng Wilson, Kenneth J. DesJarlais, Renee L. Ballentine, Shelley K. Schubert, Carsten Crysler, Carl S. Chen, Yanmin Molloy, Christopher J. Chaikin, Margery A. Donatelli, Robert R. Yurkow, Edward Zhou, Zhao Player, Mark R. Tomczuk, Bruce E. |
| ppnlink |
ELV000272361 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.bmcl.2013.09.061 |
| up_date |
2024-07-06T20:44:58.510Z |
| _version_ |
1803863928089870336 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV011755504</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625110201.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2013 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.bmcl.2013.09.061</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2013016000014.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV011755504</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0960-894X(13)01135-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">540</subfield><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">630</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">22</subfield><subfield code="2">ssgn</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">46.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Illig, Carl R.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Enhancement of kinase selectivity in a potent class of arylamide FMS inhibitors</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Structure–activity relationship (SAR) studies on a highly potent series of arylamide FMS inhibitors were carried out with the aim of improving FMS kinase selectivity, particularly over KIT. Potent compound 17r (FMS IC50 0.7nM, FMS cell IC50 6.1nM) was discovered that had good PK properties and a greater than fivefold improvement in selectivity for FMS over KIT kinase in a cellular assay relative to the previously reported clinical candidate 4. This improved selectivity was manifested in vivo by no observed decrease in circulating reticulocytes, a measure of bone safety, at the highest studied dose. Compound 17r was highly active in a mouse pharmacodynamic model and demonstrated disease-modifying effects in a dose-dependent manner in a strep cell wall-induced arthritis model of rheumatoid arthritis in rats.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Structure–activity relationship (SAR) studies on a highly potent series of arylamide FMS inhibitors were carried out with the aim of improving FMS kinase selectivity, particularly over KIT. Potent compound 17r (FMS IC50 0.7nM, FMS cell IC50 6.1nM) was discovered that had good PK properties and a greater than fivefold improvement in selectivity for FMS over KIT kinase in a cellular assay relative to the previously reported clinical candidate 4. This improved selectivity was manifested in vivo by no observed decrease in circulating reticulocytes, a measure of bone safety, at the highest studied dose. Compound 17r was highly active in a mouse pharmacodynamic model and demonstrated disease-modifying effects in a dose-dependent manner in a strep cell wall-induced arthritis model of rheumatoid arthritis in rats.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Rheumatoid arthritis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Colony-stimulating factor-1 receptor</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Macrophage colony-stimulating factor</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">KIT</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Hypocellularity</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">FMS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Anti-inflammatory</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Manthey, Carl L.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Meegalla, Sanath K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wall, Mark J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chen, Jinsheng</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wilson, Kenneth J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">DesJarlais, Renee L.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ballentine, Shelley K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schubert, Carsten</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Crysler, Carl S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chen, Yanmin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Molloy, Christopher J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chaikin, Margery A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Donatelli, Robert R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yurkow, Edward</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhou, Zhao</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Player, Mark R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tomczuk, Bruce E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Torrecillas, S. ELSEVIER</subfield><subfield code="t">Feeding European sea bass (</subfield><subfield code="d">2018</subfield><subfield code="d">a Tetrahedron publication for rapid dissemination of preliminary communications on all aspects of bioorganic chemistry, medicinal chemistry, bioinorganic chemistry and related disciplines</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000272361</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:23</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:23</subfield><subfield code="g">day:1</subfield><subfield code="g">month:12</subfield><subfield code="g">pages:6363-6369</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.bmcl.2013.09.061</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">46.00</subfield><subfield code="j">Tiermedizin: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">23</subfield><subfield code="j">2013</subfield><subfield code="e">23</subfield><subfield code="b">1</subfield><subfield code="c">1201</subfield><subfield code="h">6363-6369</subfield><subfield code="g">7</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">540</subfield></datafield></record></collection>
|
| score |
7.4017067 |